Vivaldi Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vivaldi Biosciences leverages its proprietary Delta NS1 platform to create intranasal, broadly protective vaccines. The platform's key innovation is the deletion of the NS1 gene, which disables viral replication and, uniquely, induces a potent local interferon response for enhanced mucosal and systemic immunity. With its lead universal flu vaccine, DeltaFLU, in Phase 2 and a combination COVID-19/flu candidate in preclinical development, Vivaldi aims to address significant unmet needs in respiratory disease prevention through a needle-free, potentially more effective vaccination strategy.

Infectious DiseaseRespiratory Diseases

Technology Platform

Delta NS1: A replication-deficient, intranasal vaccine vector based on an influenza A virus with the NS1 gene deleted. It is self-adjuvanting by inducing interferon and can express foreign antigens to create broadly protective vaccines.

Opportunities

A successful universal influenza vaccine could capture a multi-billion dollar market dissatisfied with current vaccine efficacy.

The nasal spray delivery and combination vaccine approach offers differentiation, potentially improving compliance and addressing public health needs for dual protection against major respiratory viruses.

Risk Factors

The company faces significant clinical development risk, as its novel platform must prove superior efficacy in large trials.

It operates in a highly competitive space against large, well-funded players and is dependent on raising capital as a pre-revenue, private entity.

Competitive Landscape

Vivaldi competes in the universal flu vaccine space against companies like Vaccitech, FluGen, and BiondVax, and large pharma (GSK, Sanofi). In intranasal COVID-19/flu vaccines, it faces competition from Codagenix, AstraZeneca, and others. Its differentiation lies in the specific interferon-inducing mechanism of its Delta NS1 platform.

More companies in Biologics / Biosimilars →More companies in United States →